Last reviewed · How we verify
LCP-tacrolimus QD + MMF QD then MMF QD
LCP-tacrolimus is a prolonged-release formulation of tacrolimus that suppresses T-cell activation and proliferation, combined with mycophenolate mofetil (MMF) which inhibits inosine monophosphate dehydrogenase to reduce lymphocyte proliferation, together providing dual immunosuppression.
LCP-tacrolimus is a prolonged-release formulation of tacrolimus that suppresses T-cell activation and proliferation, combined with mycophenolate mofetil (MMF) which inhibits inosine monophosphate dehydrogenase to reduce lymphocyte proliferation, together providing dual immunosuppression. Used for Organ transplant rejection prevention (renal, cardiac, hepatic transplantation).
At a glance
| Generic name | LCP-tacrolimus QD + MMF QD then MMF QD |
|---|---|
| Sponsor | University Hospital, Limoges |
| Drug class | Calcineurin inhibitor + antimetabolite immunosuppressant combination |
| Target | Calcineurin (tacrolimus); inosine monophosphate dehydrogenase type II (MMF) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
Tacrolimus is a calcineurin inhibitor that blocks IL-2 production and T-cell activation by inhibiting the phosphatase calcineurin. MMF selectively inhibits type II inosine monophosphate dehydrogenase, preferentially affecting T and B lymphocyte proliferation. The combination provides synergistic immunosuppression for transplant rejection prevention, with LCP-tacrolimus offering once-daily dosing convenience compared to immediate-release formulations.
Approved indications
- Organ transplant rejection prevention (renal, cardiac, hepatic transplantation)
Common side effects
- Nephrotoxicity
- Neurotoxicity (tremor, headache)
- Hyperglycemia
- Hypertension
- Gastrointestinal disturbances (diarrhea, nausea)
- Infections
- Leukopenia
Key clinical trials
- Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY) (PHASE4)
- Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: